Total trials
240
Active
66
Phase 3
9
Total enrollment
46,606
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Somatostatin analog | — | — | — | — | — | 1 | |
| Glucose 5% for fluid creep | — | — | — | — | — | 1 | |
| NaCl 0.9% (normal saline) for fluid creep | — | — | — | — | — | 1 | |
| PlasmaLyte as maintenance fluid | — | — | — | — | — | 1 | |
| NaCl 0.3% in glucose 3.3% as maintenance fluid | — | — | — | — | — | 1 | |
| Withdrawal of calcineurin-inhibitor, continue on concentration-controlled mycophenolate mofetil and corticosteroids. | — | — | — | — | — | 1 | |
| acetylsalicylic acid | — | — | — | — | — | 1 | |
| Methylprednisolone 125 MG | — | — | — | — | — | 1 | |
| tolerogenic dendritic cells | — | — | — | — | 3 | ||
| Dendritic cell vaccination | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| Platinum/pemetrexed based chemotherapy | — | — | — | — | — | 1 | |
| Dendritic cell vaccine plus temozolomide chemotherapy | — | — | — | — | — | 1 | |
| Neoadjuvant chemo-immunotherapy | — | — | — | — | — | 1 | |
| Metformin Hydrochloride 850 mg Oral | — | — | — | — | — | 1 | |
| Venetoclax | — | — | — | — | — | 1 | |
| 6-mercaptopurine | — | — | — | — | — | 1 | |
| DNA-methylation in saliva | — | — | — | — | — | 1 |
Next readouts
- 2024-12
- 2026-10-01
- 2026-12-31
- 2027-01-01
- 2027-02-28
- 2027-07
- 2027-10
- 2027-12-31
- 2028-04-30
- 2028-06
Top conditions
- Obstructive Sleep Apnea16
- Tinnitus8
- Multiple Sclerosis5
- Surgery5
- Sleep Apnea4
- Chronic Obstructive Pulmonary Disease4
- Type 1 Diabetes4
- Healthy3
Frequently asked questions about University Hospital, Antwerp
- How many clinical trials does University Hospital, Antwerp have on ClinicalTrials.gov?
- University Hospital, Antwerp is listed as the lead sponsor on 240 clinical trials in ClinicalTrials.gov, 66 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University Hospital, Antwerp's trials are in Phase 3?
- 9 of University Hospital, Antwerp's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does University Hospital, Antwerp focus on?
- University Hospital, Antwerp's most-studied conditions on ClinicalTrials.gov are Obstructive Sleep Apnea, Tinnitus, Multiple Sclerosis, Surgery, Sleep Apnea.
- When are University Hospital, Antwerp's next clinical trial readouts?
- University Hospital, Antwerp has 10 upcoming primary-completion readouts tracked here; the soonest is “Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia”, expected around 2024-12.